Novadel Pharma Inc (NVDL) 0.0054 $NVDL
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
NovaDel Announces Proposed Actions to Complete Liquidation of Assets and Cash Distribution to Shareholders
Business Wire - Wed Mar 26, 7:49AM CDT
As previously reported, NovaDel Pharma Inc. (NVDL.PK) is in the process of selling its assets in anticipation of liquidating the company and distributing its remaining cash to shareholders. Previously, Novadel has (i) sold its NovaMist(TM) patents and trademarks to SUDA LTD in exchange for cash and SUDA Common Stock and Options, (ii) sold its NitroMist(TM) patents and Trademarks and the NitroMist license to Akrimax, and (iii) entered into an agreement to sell the intellectual property and license to ECR for ZolpiMist(TM) for the assumption of the amount due to the FDA relating to ZolpiMist. This agreement is subject to the buyer obtaining financing. If financing is obtained, this sale should close by the end of April 2014.
NovaDel Pharma Inc divests USD2.4m NitroMist NDA
M2 - Wed Nov 20, 6:09AM CST
Specialist pharmaceutical company NovaDel Pharma Inc revealed on Tuesday that it has sold its NitroMist New Drug Application for approximately USD2.4m.
NovaDel Announces the Sale of its NitroMist(R) New Drug Application, License and Intellectual Property to Mist Pharmaceuticals, LLC.
Business Wire - Tue Nov 19, 3:01PM CST
NovaDel Pharma Inc. (NVDL.PK) has sold its NitroMist(R) New Drug Application to Mist Pharmaceuticals, LLC.
Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Erectile Dysfunction - Pipeline Review, H2 2013: An Overview of Pipeline Products for Erectile Dysfunction
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l84sw4/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Erectile Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical - Dong-A Pharmaceutical Co., Ltd. - FCB-Pharmicell Co.,Ltd. - Fabre-Kramer Pharmaceuticals, Inc. - Futura Medical plc. - Global Health Ventures Inc. - IntelGenx Technologies Corp. - Medisyn Technologies, Inc. - NexMed, Inc. - NovaDel Pharma, Inc. - Palatin Technologies, Inc. - Sanofi-Aventis - Senetek PLC - VIVUS, Inc. - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/l84sw4/erectile About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NovaDel Pharma Inc announces sale of assets to Suda Ltd
M2 - Wed Aug 14, 7:47AM CDT
Specialist pharmaceutical company NovaDel Pharma Inc (OTC Pink:NVDL) reported on Tuesday the completion of the divestiture of substantially all of its assets to Suda Ltd.
NovaDel Announces Completion of the Sale of Substantially All Assets to Suda Ltd.
Business Wire - Tue Aug 13, 3:01PM CDT
NovaDel Pharma Inc. ("NovaDel" or "the Company"
(OTC Pink: NVDL) announced today the completion of the sale of substantially all of the Company's assets to Suda Ltd. (the "Suda Transaction" .
Sleep Disorders - Pipeline Review, H2 2013 Features Players such as Ono Pharmaceutical Co., Ltd and
M2 - Thu Aug 08, 11:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xc32xz/sleep_disorders) has announced the addition of the "Sleep Disorders - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Disorders. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Sleep Disorders. - A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sleep Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Athersys, Inc. - CoLucid Pharmaceuticals, Inc. - Ferrer Internacional S.A. - Neurim Pharmaceuticals (1991) Ltd. - NovaDel Pharma, Inc. - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/xc..._disorders About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Suda Ltd to acquire assets of NovaDel Pharma Inc
M2 - Mon Jul 22, 3:05AM CDT
Specialty pharmaceutical company NovaDel Pharma Inc (OTC Pink: NVDL) announced on Friday the approval by its stockholders, during the Special Meeting of Stockholders held on 19 July 2013, of the sale of substantially all of the company's assets to Suda Ltd.
NovaDel Announces Stockholder Approval of Sale of Substantially All Assets to Suda Ltd.
Business Wire - Fri Jul 19, 4:55PM CDT
NovaDel Pharma Inc. ("NovaDel" or the "Company" (OTC Pink: NVDL) announced today that, during the Special Meeting of the Company's Stockholders held on July 19, 2013, its stockholders approved the sale of substantially all of the Company's assets to Suda Ltd. (the "Suda Transaction" . However, approval for the liquidation and dissolution of the Company was not received by the requisite number of stockholders and therefore the proposal did not pass. Therefore, NovaDel will not file for dissolution at this time and will continue to pursue alternative avenues in order to maximize stockholder value.
NovaDel Announces Adjournment of Special Stockholder Meeting
Business Wire - Thu Jun 27, 10:32AM CDT
--NovaDel Stockholders Are Urged To Vote FOR the Proposals
Male Sexual Dysfunction - Global Pipeline Review, H1 2013
M2 - Fri Jun 21, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44glgt/male_sexual) has announced the addition of the "Male Sexual Dysfunction - Pipeline Review, H1 2013" report to their offering. 'Male Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. Scope - A snapshot of the global therapeutic scenario for Male Sexual Dysfunction. - A review of the Male Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on
NovaDel Pharma Inc plans to divest NovaMist technology and certain other assets
M2 - Tue Apr 09, 10:44AM CDT
Pharmaceutical company NovaDel Pharma Inc (OTC Markets:NVDL.PK) stated on Monday that it has entered into a definitive agreement to sell its NovaMist technology and certain other assets.
NovaDel Announces the Signing of a Definitive Agreement to Sell its NovaMist(TM) Technology and Certain Other Assets
Business Wire - Mon Apr 08, 7:30AM CDT
NovaDel Pharma Inc. (NVDL.PK) has signed a definitive agreement to sell its NovaMist(TM) technology and certain other assets to SUDA LTD, an Australian publicly held pharmaceutical company.
NovaDel Pharma Inc's net loss narrows to USD471,000 in 2012
M2 - Thu Mar 28, 8:33AM CDT
Pharmaceutical company NovaDel Pharma Inc (OTC Markets:NVDL) reported on Wednesday its net loss of USD1.2m (USD0.01 per share) for the 12 months ended 31 December 2012.
Sleep Disorders - Pipeline Review, H1 2013
M2 - Thu Mar 28, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwv5bk/sleep_disorders) has announced the addition of the "Sleep Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sleep Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects.It also reviews key players involved in the therapeutic development for Sleep Disorders. Scope - A snapshot of the global therapeutic scenario for Sleep Disorders. - A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of mono
NovaDel Reports Unaudited Financial Results for the Twelve Months Ended December 31, 2012
Business Wire - Wed Mar 27, 7:00AM CDT
NovaDel Pharma Inc. (NVDL.PK) reported unaudited financial results for the twelve months ended December 31, 2012.
Anxiety Disorders - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/nw7hxn/anxiety_disorders) has announced the addition of Global Markets Direct's new report "Anxiety Disorders - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Anxiety Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anxiety Disorders. Anxiety Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anxiety Disorders. - A review of the Anxiety Disorders products under development by companies and universities/research institutes base
NovaDel Announces Preliminary Agreement to Sell its NovaMist(TM) Technology
Business Wire - Wed Dec 26, 3:00PM CST
NovaDel Pharma Inc. (NVDL.PK) has signed a preliminary agreement to sell its NovaMist(TM) technology to SUDA LTD, an Australian publicly held pharmaceutical company.
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
NovaDel Announces Proposed Actions to Complete Liquidation of Assets and Cash Distribution to Shareholders
Business Wire - Wed Mar 26, 7:49AM CDT
As previously reported, NovaDel Pharma Inc. (NVDL.PK) is in the process of selling its assets in anticipation of liquidating the company and distributing its remaining cash to shareholders. Previously, Novadel has (i) sold its NovaMist(TM) patents and trademarks to SUDA LTD in exchange for cash and SUDA Common Stock and Options, (ii) sold its NitroMist(TM) patents and Trademarks and the NitroMist license to Akrimax, and (iii) entered into an agreement to sell the intellectual property and license to ECR for ZolpiMist(TM) for the assumption of the amount due to the FDA relating to ZolpiMist. This agreement is subject to the buyer obtaining financing. If financing is obtained, this sale should close by the end of April 2014.
NovaDel Pharma Inc divests USD2.4m NitroMist NDA
M2 - Wed Nov 20, 6:09AM CST
Specialist pharmaceutical company NovaDel Pharma Inc revealed on Tuesday that it has sold its NitroMist New Drug Application for approximately USD2.4m.
NovaDel Announces the Sale of its NitroMist(R) New Drug Application, License and Intellectual Property to Mist Pharmaceuticals, LLC.
Business Wire - Tue Nov 19, 3:01PM CST
NovaDel Pharma Inc. (NVDL.PK) has sold its NitroMist(R) New Drug Application to Mist Pharmaceuticals, LLC.
Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Erectile Dysfunction - Pipeline Review, H2 2013: An Overview of Pipeline Products for Erectile Dysfunction
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l84sw4/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Erectile Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical - Dong-A Pharmaceutical Co., Ltd. - FCB-Pharmicell Co.,Ltd. - Fabre-Kramer Pharmaceuticals, Inc. - Futura Medical plc. - Global Health Ventures Inc. - IntelGenx Technologies Corp. - Medisyn Technologies, Inc. - NexMed, Inc. - NovaDel Pharma, Inc. - Palatin Technologies, Inc. - Sanofi-Aventis - Senetek PLC - VIVUS, Inc. - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/l84sw4/erectile About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NovaDel Pharma Inc announces sale of assets to Suda Ltd
M2 - Wed Aug 14, 7:47AM CDT
Specialist pharmaceutical company NovaDel Pharma Inc (OTC Pink:NVDL) reported on Tuesday the completion of the divestiture of substantially all of its assets to Suda Ltd.
NovaDel Announces Completion of the Sale of Substantially All Assets to Suda Ltd.
Business Wire - Tue Aug 13, 3:01PM CDT
NovaDel Pharma Inc. ("NovaDel" or "the Company"
(OTC Pink: NVDL) announced today the completion of the sale of substantially all of the Company's assets to Suda Ltd. (the "Suda Transaction" . Sleep Disorders - Pipeline Review, H2 2013 Features Players such as Ono Pharmaceutical Co., Ltd and
M2 - Thu Aug 08, 11:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xc32xz/sleep_disorders) has announced the addition of the "Sleep Disorders - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Disorders. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Sleep Disorders. - A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sleep Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Athersys, Inc. - CoLucid Pharmaceuticals, Inc. - Ferrer Internacional S.A. - Neurim Pharmaceuticals (1991) Ltd. - NovaDel Pharma, Inc. - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/xc..._disorders About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Suda Ltd to acquire assets of NovaDel Pharma Inc
M2 - Mon Jul 22, 3:05AM CDT
Specialty pharmaceutical company NovaDel Pharma Inc (OTC Pink: NVDL) announced on Friday the approval by its stockholders, during the Special Meeting of Stockholders held on 19 July 2013, of the sale of substantially all of the company's assets to Suda Ltd.
NovaDel Announces Stockholder Approval of Sale of Substantially All Assets to Suda Ltd.
Business Wire - Fri Jul 19, 4:55PM CDT
NovaDel Pharma Inc. ("NovaDel" or the "Company"
(OTC Pink: NVDL) announced today that, during the Special Meeting of the Company's Stockholders held on July 19, 2013, its stockholders approved the sale of substantially all of the Company's assets to Suda Ltd. (the "Suda Transaction" . However, approval for the liquidation and dissolution of the Company was not received by the requisite number of stockholders and therefore the proposal did not pass. Therefore, NovaDel will not file for dissolution at this time and will continue to pursue alternative avenues in order to maximize stockholder value. NovaDel Announces Adjournment of Special Stockholder Meeting
Business Wire - Thu Jun 27, 10:32AM CDT
--NovaDel Stockholders Are Urged To Vote FOR the Proposals
Male Sexual Dysfunction - Global Pipeline Review, H1 2013
M2 - Fri Jun 21, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44glgt/male_sexual) has announced the addition of the "Male Sexual Dysfunction - Pipeline Review, H1 2013" report to their offering. 'Male Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. Scope - A snapshot of the global therapeutic scenario for Male Sexual Dysfunction. - A review of the Male Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on
NovaDel Pharma Inc plans to divest NovaMist technology and certain other assets
M2 - Tue Apr 09, 10:44AM CDT
Pharmaceutical company NovaDel Pharma Inc (OTC Markets:NVDL.PK) stated on Monday that it has entered into a definitive agreement to sell its NovaMist technology and certain other assets.
NovaDel Announces the Signing of a Definitive Agreement to Sell its NovaMist(TM) Technology and Certain Other Assets
Business Wire - Mon Apr 08, 7:30AM CDT
NovaDel Pharma Inc. (NVDL.PK) has signed a definitive agreement to sell its NovaMist(TM) technology and certain other assets to SUDA LTD, an Australian publicly held pharmaceutical company.
NovaDel Pharma Inc's net loss narrows to USD471,000 in 2012
M2 - Thu Mar 28, 8:33AM CDT
Pharmaceutical company NovaDel Pharma Inc (OTC Markets:NVDL) reported on Wednesday its net loss of USD1.2m (USD0.01 per share) for the 12 months ended 31 December 2012.
Sleep Disorders - Pipeline Review, H1 2013
M2 - Thu Mar 28, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwv5bk/sleep_disorders) has announced the addition of the "Sleep Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sleep Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects.It also reviews key players involved in the therapeutic development for Sleep Disorders. Scope - A snapshot of the global therapeutic scenario for Sleep Disorders. - A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of mono
NovaDel Reports Unaudited Financial Results for the Twelve Months Ended December 31, 2012
Business Wire - Wed Mar 27, 7:00AM CDT
NovaDel Pharma Inc. (NVDL.PK) reported unaudited financial results for the twelve months ended December 31, 2012.
Anxiety Disorders - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/nw7hxn/anxiety_disorders) has announced the addition of Global Markets Direct's new report "Anxiety Disorders - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Anxiety Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anxiety Disorders. Anxiety Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anxiety Disorders. - A review of the Anxiety Disorders products under development by companies and universities/research institutes base
NovaDel Announces Preliminary Agreement to Sell its NovaMist(TM) Technology
Business Wire - Wed Dec 26, 3:00PM CST
NovaDel Pharma Inc. (NVDL.PK) has signed a preliminary agreement to sell its NovaMist(TM) technology to SUDA LTD, an Australian publicly held pharmaceutical company.
